Skip to Content

Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Download PQI pdf 0.21MB

By: Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO

About this PQI

The purpose of this PQI is to discuss clinical considerations around the use of zanubrutinib (Brukinsa®) to optimize outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI